(19)
(11)EP 3 456 333 B8

(12)CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15)Correction information:
Corrected version no 1 (W1 B1)

(48)Corrigendum issued on:
13.05.2020 Bulletin 2020/20

(45)Mention of the grant of the patent:
01.04.2020 Bulletin 2020/14

(21)Application number: 18196690.4

(22)Date of filing:  15.11.2013
(51)Int. Cl.: 
A61K 31/7088  (2006.01)
A61P 35/00  (2006.01)
A61P 7/00  (2006.01)
A61K 31/7125  (2006.01)
A61P 35/02  (2006.01)
A61P 7/06  (2006.01)

(54)

USE OF THE TELOMERASE INHIBITOR IMETELSTAT FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROME

VERWENDUNG VOM TELOMERASE-HEMMER IMETELSTAT ZUR BEHANDLUNG DES MYELODYSPLASTISCHEN SYNDROMS

UTILISATION DE L'INHIBITEUR DE LA TÉLOMÉRASE IMETELSTAT POUR LE TRAITEMENT DU SYNDROME MYÉLODYSPLASIQUE


(84)Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME

(30)Priority: 07.12.2012 US 201261734941 P
15.03.2013 US 201361799069 P
15.03.2013 US 201313841711
05.11.2013 US 201361900347 P

(43)Date of publication of application:
20.03.2019 Bulletin 2019/12

(62)Application number of the earlier application in accordance with Art. 76 EPC:
13861008.4 / 2928477

(73)Proprietor: Geron Corporation
Foster City, CA 94404 (US)

(72)Inventors:
  • STUART, Monic, J.
    Hillsborough, CA 94010 (US)
  • KELSEY, Stephen
    Palo Alto, CA 94301 (US)

(74)Representative: Bassil, Nicholas Charles 
Kilburn & Strode LLP Lacon London 84 Theobalds Road
London WC1X 8NL
London WC1X 8NL (GB)


(56)References cited: : 
CN-A- 101 220 044
US-A1- 2005 282 893
  
  • GABRIELA M BAERLOCHER ET AL: "Imetelstat Rapidly Induces and Maintains Substantial Hematologic and Molecular Responses in Patients with Essential Thrombocythemia (ET) Who Are Refractory or Intolerant to Prior Therapy: Preliminary Phase II Results", ANNUAL MEETING OF THE AM SOCIETY, vol. 120, no. 21, 16 November 2012 (2012-11-16), pages 1-16, XP055254428,
  • KAKIUCHI YASUTAKA ET AL: "Inhibition of Human Tumor Cell Proliferation by the Telomerase Inhibitor TELIN", CYTOLOGIA (TOKYO), vol. 75, no. 2, June 2010 (2010-06), pages 177-183, XP008180568, ISSN: 0011-4545
  • TAUCHI TETSUZO ET AL: "Activity of a novel G-quadruplex-interactive telomerase inhibitor, SOT-095, against human leukemia cells: Involvement of ATM-dependent DNA damage response pathways", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US , vol. 102, no. 11 16 November 2003 (2003-11-16), page 652a, XP008180575, ISSN: 0006-4971 Retrieved from the Internet: URL:http://www.bloodjournal.org/
  • BAERLOCHER GABRIELA M ET AL: "Imetelstat Rapidly Induces and Maintains Substantial Hematologic and Molecular Responses in Patients with Essential Thrombocythemia (ET) Who Are Refractory or Intolerant to Prior Therapy: Preliminary Phase II Results", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US , vol. 120, no. 21 1 November 2012 (2012-11-01), page 179, XP008180577, ISSN: 0006-4971 Retrieved from the Internet: URL:http://www.bloodjournal.org/
  • CLAUDIO BRUNOLD ET AL: "3843: Imetelstat, A Potent Telomerase Inhibitor, Inhibits the Spontaneous Growth of CFU-Meg In Vitro From Essential Thrombocythemia Patients but Not From Healthy Individuals", BLOOD, vol. 118, no. 21, 18 November 2011 (2011-11-18), - 13 December 2011 (2011-12-13), page 3843, XP055254840, US ISSN: 0006-4971
  • CATENACCI ET AL: "Myelodysplasic syndromes: A comprehensive review", BLOOD REVIEWS, CHURCHILL LIVINGSTONE, AMSTERDAM, NL, vol. 19, no. 6, 1 November 2005 (2005-11-01), pages 301-319, XP005167052, ISSN: 0268-960X, DOI: 10.1016/J.BLRE.2005.01.004
  • FENAUX ET AL (POSTER 4256) ASH (2017): POSTER, 2017,
  • STEENSMA ET AL (ABSTRACT 463) ASH (2018): ASH ORAL PRESENTATION, 2018,
  • STEENSMA ET AL (ABSTRACT S1557) EHA (2018): EUROPEAN HEMATOLOGY ASSOCIATION, 2018,
  
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).